Company news
Sunshine Biopharma Inc. news in 2022
Sunshine Biopharma Inc.'s news releases, calls and decks from 2022, newest first.
Sunshine Biopharma’s Annual Letter to Shareholders
December 19, 2022
Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project
November 15, 2022
Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue
October 19, 2022
Sunshine Biopharma Files Its Second Quarter Report With the SEC
August 3, 2022
Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona
July 27, 2022
Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market
April 27, 2022
Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market
April 25, 2022
Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells
April 24, 2022
Sunshine Biopharma’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells
April 4, 2022
Sunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-Market
March 13, 2022
Sunshine Biopharma, Inc. Announces Pricing of $8.0 Million Private Placement Priced At-the-Market
March 9, 2022
Sunshine Biopharma Expands Anti-Coronavirus Drug Development Program By Signing A Collaboration Agreement With The University Of Arizona
February 24, 2022
Sunshine Biopharma, Inc. Announces Closing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market
February 16, 2022
Sunshine Biopharma, Inc. Announces Pricing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market
February 14, 2022
Decks in 2022
- Investor Presentation (February 2022)
Investor deck · 15 slides · Feb 8, 2022